Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Japan Tissue Engineering Co., Ltd.
  6. News
  7. Summary
    7774   JP3389610001

JAPAN TISSUE ENGINEERING CO., LTD.

(7774)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Japan Tissue Engineering Co., Ltd. Announces Marketing Approval of Autologous Cultured Oral Mucosal Epithelial Cell Sheet

05/24/2021 | 04:40am EST

Japan Tissue Engineering Co., Ltd. announced that marketing approval of autologous cultured oral mucosal epithelial cell sheet (Development Name: COMET01) for the treatment of limbal stem cell deficiency (LSCD) *1 has been reviewed and acknowledged at today's meeting of the Regenerative Medical Products and Biological Technology Subcommittee of the Ministry of Health, Labour and Welfare's Pharmaceutical Affairs and Food Sanitation Council. COMET01 is epithelial cell sheet derived from human (autologous) oral mucosa. It is prepared by harvesting oral mucosal tissue from the patient and then cultivating the isolated cells. The purpose of this product is to repair defective corneal epithelium by transplanting the sheet onto the ocular surface, where the patient's own oral mucosal epithelial cells become engrafted and epithelialize. COMET01 is a promising new treatment method for patients who have extensive damage to the cornea of both eyes and markedly reduced visual acuity owing to LSCD. COMET01 was designated a regenerative medical product for orphan diseases *2 -- specifically the treatment of LSCD -- in 2020. J-TEC introduced the transplantation technique for autologous cultured oral mucosal epithelial cell sheets developed by Professor Kohji Nishida of Graduate School of Medicine/Faculty of Medicine, Osaka University (Department of Neural and Sensory Organ Surgery (Department of Ophthalmology)) and has taken over the investigator-initiated trial conducted by Professor Nishida's group, conducting it in the form of a company-sponsored clinical trial of COMET01 since September of 2016. In September of 2020, J-TEC submitted an application for marketing approval of COMET01to the Ministry of Health, Labour and Welfare as Japan's second regenerative medical product in the ophthalmology field. Marketing of COMET01 is to be conducted by Nidek Co., Ltd. (Gamagori City, Aichi Prefecture; President and CEO, Motoki Ozawa), a maker of ophthalmology and optometry products. As the top runner in regenerative medicine in Japan, J-TEC obtained marketing approval for autologous cultured epidermis "JACE", Japan's first regenerative medical product, in 2007 and began marketing JACE in 2009. Marketing approval was then obtained for autologous cultured cartilage "JACC" in 2013 and for autologous cultured corneal epithelium "NEPIC" *3 in March of 2020. JACC was Japan's first regenerative medical product in the orthopedic surgery field, and NEPIC was the first in the ophthalmology field. Through the practical application of first NEPIC and then COMET01, J-TEC has succeeded in providing a treatment method for corneal epithelial diseases for which no curative therapy previously existed. By reinforcing sales of existing products and accelerating development of new regenerative medical products, J-TEC is promoting the development of regenerative medicine into an industry while also contributing to the improvement of patients' quality of life (QOL).


ę S&P Capital IQ 2021
All news about JAPAN TISSUE ENGINEERING CO., LTD.
11/26Japan Tissue Starts Clinical Trial of Treatment for Dermal Burns
MT
11/24Japan Tissue Engineering Co., Ltd. Announces Start of Clinical Trial for Allogeneic Cul..
CI
10/29Japan Tissue Engineering Co., Ltd. Reports Earnings Results for the Half Year Ended Sep..
CI
09/20JAPAN TISSUE ENGINEERING CO., LTD.(J : 7774) dropped from S&P Global BMI Index
CI
09/14Japan Tissue Engineering Co., Ltd. Announces Approval of Autologous Cultured Oral Mucos..
CI
07/30Japan Tissue Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended..
CI
07/30Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Year Ending March..
CI
06/17Japan Tissue Engineering Co., Ltd. Announces Approval Obtained for Autologous Cultured ..
CI
05/24Japan Tissue Engineering Co., Ltd. Announces Marketing Approval of Autologous Cultured ..
CI
04/28Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for Fiscal Year Ending Ma..
CI
More news
Financials
Sales 2022 3 602 M 31,7 M 31,7 M
Net income 2022 234 M 2,06 M 2,06 M
Net Debt 2022 - - -
P/E ratio 2022 107x
Yield 2022 1,31%
Capitalization 24 894 M 220 M 219 M
Capi. / Sales 2022 6,91x
Capi. / Sales 2023 5,35x
Nbr of Employees 200
Free-Float 27,6%
Chart JAPAN TISSUE ENGINEERING CO., LTD.
Duration : Period :
Japan Tissue Engineering Co., Ltd. Technical Analysis Chart | 7774 | JP3389610001 | MarketScreener
Technical analysis trends JAPAN TISSUE ENGINEERING CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 613,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Ken-ichiro Hata Executive President & Representative Director
Yukio Mori Executive Officer & Manager-Production Technology
Masukazu Iie Executive Officer, Manager-Research & Development
Masahito Obayashi Head-Personnel, Accounting & Compliance
Toshihiro Osuka Director & Senior Managing Executive Officer
Sector and Competitors